Assessment of Dosimetric Accuracy and Plan Quality in Prostate SBRT: Retrospective Evaluation of 36.25 Gy in 5 Fractions Using RapidArc on Varian Millennium MLC with MLC Parameter Analysis

Ajithkumar M⬚

Department of Radiotherapy, Meherbai Tata Memorial Hospital, Jamshedpur, India

makumar735@gmail.com

Subhankar Show

Department of Radiotherapy, Meherbai Tata Memorial Hospital, Jamshedpur, India

subhankarshow003@gmail.com

Aaditya Prakash

Department of Radiotherapy, Tata Main Hospital, Jamshedpur, India

aaditya.prakash@tatasteel.com

Abstract

Introduction

Prostate cancer is one of the most commonly diagnosed cancers among men worldwide. Advances in radiotherapy, particularly Stereotactic Body Radiotherapy (SBRT), have enabled ultra-hypofractionated treatment schedules that enhance tumor control while reducing treatment time. This study focuses on evaluating the dosimetric accuracy and plan quality of prostate SBRT using RapidArc technology on a Varian Millennium Multileaf Collimator (MLC) system.

Materials and Methods

A total of 24 patients with localized prostate adenocarcinoma received SBRT with a prescribed dose of 36.25 Gy in five fractions. Treatment planning was performed using Eclipse v15.6 with Acuros XB algorithm, utilizing three 6 MV flattening filter-free (FFF) arcs. Planning Target Volume (PTV) coverage, OAR doses, Paddick Conformity Index (PCI), Gradient Index (GI), and Monitor Units (MU) were analyzed. Multileaf collimator motion was evaluated through log files, including leaf speed and position dynamics. Quality assurance was performed using electronic portal imaging devices (EPID) and gamma pass rate evaluation.

Results

The mean PTV D_{95} was 35.80 ± 0.46 Gy, with mean Dmax and Dmean being 39.80 ± 1.05 Gy and 37.10 ± 0.40 Gy, respectively. $V_{95\%}$ averaged 99.13 ± 1.14%, confirming adequate coverage. Slight violations of rectum and bladder Dmax constraints were observed but remained clinically acceptable. The mean PCI and GI were 0.905 ± 0.18 and 3.08 ± 0.16, respectively. Gamma pass rates exceeded 99.6% for 2%/2 mm criteria. MLC leaf speed remained below the 2.5 cm/s threshold, ensuring mechanical safety and dose delivery accuracy.

Conclusion

Prostate SBRT delivered via RapidArc on a Varian Millennium MLC system demonstrated high plan conformity, efficient delivery, and acceptable OAR sparing. The integration of intra-fraction CBCT improved setup accuracy, while MLC analysis confirmed mechanical precision. This approach supports the clinical adoption of RapidArc-based SBRT as a feasible and effective option for localized prostate cancer treatment.

Keywords

Prostate Cancer, Dosimetric Analysis, Treatment Planning, Paddick Conformity Index, Trajectory Log Analysis, Plan Quality Metrics, Patient Specific QA

1. Introduction

Prostate cancer remains an important global health challenge, particularly affecting aging male populations worldwide. Advances in radiotherapy have revolutionized its management, with technological innovations enabling precise targeting and dose escalation to improve tumor control while minimizing adverse effects. Among these developments, SBRT has emerged as a promising treatment modality, delivering high biological doses in five fractions, thus offering a more convenient and resource-efficient alternative to conventional radiotherapy regimens[1-2].

The radiobiological rationale for hypofractionation in prostate cancer is grounded in its low alpha/beta ratio (∼1.5 Gy) [1-14], which suggests that larger doses per fraction can enhance tumor control and potentially spare normal tissues. Supporting this approach, clinical trials such as PACE-B and HYPO-RT-PC have demonstrated favorable outcomes with regimens like 36.25 Gy in five fractions, showing good tolerability and promising efficacy [3]. These findings align with the trend toward

ultra hypofractionation, which aims to optimize treatment efficacy while reducing
treatment duration, healthcare costs, and patient burden.

However, the success of such high-dose, few-fraction treatments hinges critically on
meticulous dosimetric planning. Precise delineation of target volumes and organs at
risk (OARs)—notably the bladder, rectum, and penile bulb—is essential to maximize
tumor coverage and minimize radiation exposure to surrounding normal tissues.
Techniques like advanced image-guided planning used to achieving these goals [1-
3].
While prior studies have explored SBRT for prostate cancer using RapidArc, this
work uniquely combines conventional dosimetric evaluation with a detailed
analysis of multileaf collimator (MLC) leaf speed dynamics, an understudied aspect
of treatment delivery stability. By characterizing MLC motion through leaf speed
distributions, we provide novel insights into the mechanical reliability of plan
delivery. Additionally, this study evaluates the impact of daily intra-fraction CBCT-
based image guidance on ensuring precise dose delivery in a high-dose, ultra-
hypofractionated regimen (36.25 Gy in five fractions). This integrated dosimetric
and mechanical approach offers a comprehensive assessment of treatment quality,
paving the way for refined clinical protocols and enhanced safety in prostate SBRT.

Given the ongoing evolution of prostate radiotherapy protocols and the increasing
adoption of SBRT, our study aims to evaluate the plan quality and adherence to dose
constraints in delivering prostate SBRT in five fractions. This research will
contribute to establishing standardized dosimetric guidelines, ensuring safe and
effective treatment while preserving the quality of life for patients. As the landscape
of prostate cancer treatment continues to advance, precise and validated dosimetric
planning remains the cornerstone for translating promising clinical outcomes into
routine practice.

94 2. Materials and Methods

95 2.1 Study Design and Patient Selection

This retrospective cohort study included a total of 24 patients diagnosed with
localized prostate cancer between [2022–2025] .The sample size was based on all
eligible non-metastatic cases treated during the study period. Diagnosis was
established using serum prostate-specific antigen (PSA) testing, digital rectal
examination (DRE), transrectal ultrasound-guided biopsy, and computed
tomography (CT) imaging to confirm localized disease. All patients received SBRT in

exactly five fractions, following established ultra-hypofractionation protocols for
prostate cancer.

Inclusion Criteria:-
105

1.Male patients aged 18 years or older,
2.Histologically confirmed prostate adenocarcinoma,
3.Clinical staging indicating localized disease (e.g., T1c-T3a),
4. No evidence of metastatic disease,
5.Prostate volume within the range suitable for SBRT (e.g., 90-120 cc),
6.Adequate organ function and performance status suitable for radiotherapy.
112

113 *Exclusion Criteria:-*
114

115 1.Prior pelvic radiotherapy,
116 2.Significant comorbidities contraindicating SBRT,
117 3.Presence of metastatic or locally advanced disease beyond T3a,
118 4.Inability to tolerate immobilization or imaging procedures necessary for SBRT.
119

2.2 Imaging and Target Volume Delineation

All patients underwent CT simulation with a 1 mm slice thickness using a linear
accelerator. Immobilization was performed in the supine position with knee and
foot supports. Patients followed bladder filling and rectal emptying protocols to
reduce internal organ motion. CT images were imported into the Eclipse 15.6
treatment planning system (Varian Medical Systems, Palo Alto, CA, USA) [1].

The gross tumor volume (GTV) was delineated based on MRI and PET/CT imaging,
particularly utilizing Ga-68 PSMA PET scans to identify dominant intraprostatic
lesions with high tracer uptake. The clinical target volume (CTV) included the
prostate and seminal vesicles, with a 3 mm isotropic expansion to account for
potential microscopic extension. A planning target volume (PTV) was then
generated by adding an additional 3 mm isotropic margin around the CTV to
compensate for setup uncertainties and ensure accurate dose delivery.

Organs at risk (OARs), such as the bladder, rectum, penile bulb, femoral heads, and
small bowel, were contoured following standard guidelines. The rectum extended
from the ischial tuberosities to the rectosigmoid flexure; the bladder encompassed
the entire organ. Additional OARs, including the penile bulb and femoral heads,
were contoured for dose monitoring [15-17].

2.3 Treatment Planning and Delivery

Treatment plans were developed in Eclipse 15.6 (Varian Medical Systems, Palo Alto,
CA, USA) using the Acuros XB(AXB) algorithm for dose calculation [10, 15-20]. The
prescribed dose was 36.25 Gy delivered in five fractions. Plans aimed for at least
95% of the PTV volume to receive the prescribed dose ($V_{95} \geq 95\%$), with the isodose
line set at 95% to cover the target, allowing hotspots up to approximately 111%
within the PTV.

The optimization utilized three full arcs with 6 MV flattening filter-free (FFF) photon
beams configured as Volumetric Modulated Arc Therapy (VMAT). The plan
prioritized conformality and OAR sparing, with the dose distribution normalized to
keep the 95% isodose line encompassing the PTV. Hotspots within the target were
permitted to reach up to 111% of the prescribed dose, provided they did not exceed
OAR constraints. Dose constraints included maximum doses of 40 Gy to the penile
bulb and 38 Gy to the rectum and bladder.

DVH analyses evaluated key metrics: D_{95}, Dmax, Dmean, and V_{95} for the target. The
primary target coverage metric was V_{95}, representing the percentage volume of the
PTV receiving at least 95% of the prescription dose.

2.4 Dosimetric Parameters and Plan Quality Metrics

The Paddick Conformity Index (PCI), a widely used measure of plan conformity [5,
9-12], was calculated as follows:

$PCI = (TV_{PIV})^2 / (TV \cdot PIV)$

Where:

TV_{PIV}: Target volume covered by prescription isodose volume

TV: Target volume

PIV: Prescription isodose volume

A PCI value close to 1 indicates optimal conformity between the prescribed dose
distribution and the target volume.

Gradient Index (GI)

Defined as:

$GI = PIV_{Half} / PIV$

where PIV_{half} represents the prescription isodose volume at half the prescription
isodose (e.g., at 40 %), and PIV, the full prescription isodose volume (e.g., at 80 %).
This aligns with the standard used in ICRU Report 91 for assessing dose fall-off
outside the target. A lower GI (Typically 3-4) reflects a steeper dose gradient,
indicating better normal tissue sparing.

2.5 MLC Parameters

MLC model used was the Varian Millennium 120, featuring a 5 mm leaf width at
isocenter in the central 20 cm of the field, optimized for precise beam shaping.
Maximum leaf speed was verified to remain within machine specifications (e.g., up
to 2.5 cm/s) during dynamic delivery [5]. MLC position data were recorded at 20 ms
intervals during treatment delivery. These high-frequency log files enabled detailed
analysis of leaf motion patterns, positional stability, and dynamic adaptation
throughout the arc. The mean leaf speed was computed from frame-to-frame
positional shifts to ensure accurate and consistent dose delivery (see Figures 6 and
7).

2.6 Treatment Delivery Data

MU Count: Total monitor units delivered per plan.

MLC Motion Patterns: Assessed from logged positional data to evaluate plan
complexity(Total MU/cGy) and delivery efficiency.

Treatment Times: Total beam-on time recorded to evaluate treatment efficiency

2.7 Quality Assurance and Verification

The advanced irradiation techniques in a radiotherapy clinic require extensive dose
verification measures that go beyond current routine clinical practice. Amorphous
silicon electronic portal imaging devices (a-Si EPIDs) (e.g., Varian aS1200, Varian
Medical Systems, Palo Alto, CA, USA) [15]. Pre-treatment verification was performed
using the a-Si EPID(Varian aS1200, Varian Medical Systems, Palo Alto, CA, USA)
system, with gamma passing rates evaluated at 3%/2 mm and 2%/2 mm criteria to
ensure plan accuracy. The Varian linear accelerator automatically logs thirteen
standard delivery parameters via trajectory files, including monitor units (MU),
gantry and collimator angles, MLC positions, jaw settings, dose rate, and couch
position. Among these, MU, MLC motion, and gantry angle were selected for analysis
due to their direct impact on delivery accuracy. Treatment delivery times were
optimized to improve efficiency without compromising plan quality.

2.8 Statistical Analysis

All dosimetric parameters, including D_{95}, Dmax, Dmean, V_{95}, and OAR doses, were
statistically analyzed. Descriptive statistics summarized plan quality, and
comparisons were made to assess consistency across patients. A significance
threshold of $p<0.05$ was applied.

Treatment plans were developed in Eclipse 15.6(Varian Medical Systems, Palo Alto,
CA, USA). The plans used three 6 MV FFF arcs, with the isodose line set at 95% to
ensure adequate target coverage, allowing hotspots up to 111% [3,5,7, 9-13]. The
approach emphasizes robust tumor coverage ($V_{95} \geq 95\%$) while maintaining strict
OAR constraints, aligning with current clinical practices for safe, effective ultra
hypofractionated prostate radiotherapy.

3. Results:

TABLE 1: Patient Demographics

Characteristic	Number / Details
Total Patients	24 Patients
Age (years), mean ± SD	50.0 ± 6.7
Age Range	30 – 70
Gender	Male (24 Patients)
Disease Staging (clinical T stage)	
⬜ T1c	6 patients (25%)
⬜ T2a	8 patients (33%)
⬜ T2b	5 patients (21%)
⬜ T3a	5 patients (21%)
Prostate Volume Range	90 – 120 cc

Summary of baseline demographic and clinical characteristics for 24 male patients with
localized prostate cancer treated with stereotactic body radiotherapy (SBRT) to a total dose
of 36.25 Gy in 5 fractions. Clinical T-stage distribution includes T1c to T3a disease.

Patient Demographics

A total of 24 patients were included in the study. The demographic characteristics
are summarized in Table 1. The mean age was 50.0 ± 6.7 years, with an age range

from 30 to 70 years. All patients were male and presented with localized disease at
diagnosis.

TABLE 2: Statistical Summary of Dosimetry Metrics

Structure	Metric	Average ± SD	Unit	Constraint
PTV	Dmean	37.10 ± 0.40	Gy	-
PTV	Dmax	39.80 ± 1.05	Gy	-
PTV	D_{95}	35.80 ± 0.46	Gy	≥ Prescription (36.25 Gy)
PTV	Dmin	32.51 ± 0.52	Gy	-
PTV	$V_{95 (\%)}$	99.13 ± 1.14	%	≥ 95%
Bowel Bag	Dmax	21.55 ± 1.12	Gy	< 35 Gy
Bowel Bag	V_{20Gy}	25.50 ± 69.45	cc	< 50 cc
Bladder	Dmax	38.76 ± 0.86	Gy	< 38 Gy
Bladder	V_{18Gy}	40.91 ± 13.74	%	< 50%
Rectum	Dmax	38.48± 0.70	Gy	< 38 Gy
Rectum	V_{18Gy}	44.48 ± 9.50	%	< 50%
Femoral Head (Rt)	V_{30Gy}	0.00 ± 0.00	cc	< 5 cc
Femoral Head (Lt)	V_{30Gy}	0.00 ± 0.00	cc	< 5 cc
Penile Bulb	Dmax	38.72 ± 0.81	Gy	< 40 Gy
Penile Bulb	V_{30Gy}	47.30 ± 6.69	%	< 50%

Table 2 demonstrates the Statistical Summary of Dosimetry Metrics

Dmean (Mean Dose): The average dose received by the entire PTV is approximately
37.10 Gy, with a small variation (±0.40 Gy). This indicates that, on average, the
target volume receives slightly above the prescribed dose (36.25 Gy), which can be
intentional to ensure coverage. Dmax (Maximum Dose): The highest dose within the
PTV is about 39.80 Gy (±1.05 Gy), reflecting dose hotspots or inhomogeneities,
which are common in SBRT to boost tumor control. D_{95}: The dose received by 95%
of the PTV is approximately 35.80 Gy (±0.46 Gy). It is slightly below the prescribed
dose (36.25 Gy), but still generally acceptable for ensuring adequate coverage, as it
ensures most of the target gets the intended dose. Dmin (Minimum Dose): The

lowest dose within the PTV is around 32.51 Gy, indicating some dose heterogeneity
but unlikely to compromise treatment efficacy.

Bowel Bag V_{20Gy}: A mean volume of 25.50 ± 69.45 cc received 20 Gy, with a notably
high standard deviation. This variability is likely due to inter-patient anatomical
differences and fluctuations in bladder filling, which can affect bowel positioning.
These findings underscore the importance of standardized bowel and bladder
preparation protocols to minimize dose to the bowel and improve plan consistency.
Bladder/Rectum Dmax violate constraints (p<0.05) [14, 17-19], Bowel Bag and Penile
Bulb are within limits (p>0.05) [16]. Where slight exceedances of predefined dose
constraints are observed for organs such as the bladder and rectum. Specifically, a
slight exceedance indicates that the dose to certain organs is marginally above the
established safety limits, but these levels remain close to the constraints (see Table
2).In practice, small violations may be acceptable if they do not significantly increase
the risk of toxicity or adverse effects. This approach allows for flexibility in
treatment planning, enabling clinicians to prioritize effective tumor coverage and
overall patient safety while acknowledging minor deviations from ideal constraints.

FIGURE 1: Dose-volume histogram for a representative patient demonstrating
target coverage (PTV) and sparing of OARs (bladder, rectum, penile bulb). The
dashed line indicates the prescription dose of 36.25 Gy.

FIGURE 2: Pre-treatment axial CT image of the prostate showing 50% isodose
line distribution.

FIGURE 3: Pre-treatment sagittal CT image of the prostate showing 50%
isodose line distribution.

FIGURE 4: Pre-treatment coronal CT image of the prostate showing 50% isodose line distribution.

Figure 1 illustrates the dose-volume histogram for a representative patient, demonstrating adequate target coverage and organ sparing. Figures 2, 3, and 4 show views of the 50% dose distribution, demonstrating conformal coverage of the prostate (outlined) with rapid dose fall-off outside the target.

TABLE 3: PTV Metrics vs Prescription Dose(36.25 Gy)

Metric	Mean ± SD	Interpretation	p-value
Dmean	37.10 ± 0.40 Gy	Significantly higher	<0.001
D_{95}	35.80 ± 0.46 Gy	Significantly lower	<0.001
Dmax	39.80 ± 1.05 Gy	Significantly higher	<0.001

P-values were obtained from a one-sample t-test comparing each metric to the prescribed dose of 36.25 Gy. The p-values indicate whether the mean values are significantly different from the prescribed dose.

PTV D_{95} (35.80 Gy) is below prescription (36.25 Gy) with statistical significance
(p<0.001) [9-14, 16-19]. But D_{95} covered 95% of the prescribed dose.Dmean/Dmax
exceeds prescription (p<0.001), indicating hot spots(see Table 3). In SBRT, such hot
spots are often intentionally created within the target to ensure adequate tumor
coverage due to the highly conformal and hypofractionated nature of the treatment.
These dose inhomogeneities can enhance tumor control by delivering a higher dose
to the tumor core while maintaining normal tissue constraints. However, careful
planning is essential to prevent excessive doses to surrounding tissues and
minimize toxicity.

Metric	3%/2 mm Gamma Pass Rate (%)	2%/2 mm Gamma Pass Rate (%)	Conformity Index (CI)	Gradient Index (GI)
Mean ± SD	99.94 ± 0.08	99.67 ± 0.23	0.905 ± 0.18	3.08 ± 0.16

284 **TABLE 4: Gamma Analysis and Plan Quality Metrics for Prostate SBRT Plans**

285 Table 4 illustrates the dosimetric analysis demonstrated high treatment accuracy,

286 with mean gamma pass rates of 99.94±0.08% for 3%/2mm and 99.67±0.23% for

287 2%/2mm criteria. The conformity index and gradient index were 0.905±0.18 and

288 3.08±0.16, respectively, indicating precise target coverage and sharp dose fall-off .

FIGURE 5: (A) Box plot of PTV dose distribution. (B) Relationship between PTV V_{95} and bladder V_{18Gy}. (C) PTV V_{95} versus penile bulb dose. (D) PTV V_{95} versus rectum V_{18Gy}.

Figure 5 offers visual insights into the balance between tumor coverage and sparing healthy organs during treatment planning. It includes four panels: (A) a box plot of PTV dose distribution; (B) the relationship between PTV V_{95} and bladder V_{18Gy}; (C) PTV V_{95} versus penile bulb dose; and (D) PTV V_{95} versus rectum V_{18Gy}. These panels collectively illustrate the various trade-offs involved in dose distribution.

4. Discussion:

4.1 Overview of Study

This study demonstrates that prostate SBRT delivered via RapidArc on a Varian Millennium MLC system achieves highly conformal and precise dose distributions, providing target coverage consistent with or exceeding established standards. The median PTV $D_{95\%}$ was 35.8 Gy, comparable to or slightly better than doses reported in recent clinical trials such as PACE-B, which documented an average of 34.7 ± 0.8 Gy. These results confirm that high-quality dose coverage is feasible with SBRT using RapidArc [3]. Organ at risk (OAR) parameters, including bladder Dmax (38.74 Gy), were marginally above some reported values like those from the PROFIT trial (38.5 ± 2.1 Gy). Nonetheless, these doses remained within acceptable toxicity thresholds, emphasizing that careful planning can balance tumor coverage with OAR sparing. The slight deviations highlight the importance of strict constraint application during planning and optimization.

4.2 Cohort Demographics and Their Implications

The relatively young mean age of our patient cohort (50 years) is an unusual finding, as prostate cancer is more commonly diagnosed in older men, with a median age of approximately 66 years. This age distribution may be influenced by referral patterns at our institution, where younger patients with intermediate-risk disease and good performance status are more frequently selected for SBRT. While younger patients may exhibit better tolerance to treatment-related side effects, their longer life expectancy underscores the importance of minimizing long-term toxicity and preserving quality of life post-SBRT.

4.3 Treatment Planning and Delivery Efficiency

The RapidArc approach enabled treatment times of approximately 70–90 seconds per arc, significantly reducing session duration compared to traditional methods. This rapid delivery minimizes the potential for intrafractional prostate motion; however, without real-time tracking systems, some residual uncertainties may persist. To mitigate intra-fraction motion, daily CBCT imaging was performed immediately before each arc to verify and, if necessary, correct patient positioning and prostate localization. While this protocol results in an increased imaging dose compared to single-CBCT protocols, the cumulative imaging dose was estimated to be less than **100–150 mGy per fraction**, which is considered acceptable relative to the total therapeutic dose of 36.25 Gy. Moreover, the improved geometric accuracy achieved through repeated imaging was deemed critical for high-precision SBRT.

Specifically, CBCT scans acquired before each arc allowed for precise alignment of
the prostate relative to the planning CT. This intra-fraction imaging protocol
facilitated real-time verification of treatment setup, ensuring accurate dose delivery
during each arc. [9]. Although continuous intra-fraction motion tracking was not
employed, this approach effectively minimized positional errors between arcs and
maintained high dosimetric accuracy. Our dosimetric verification confirmed the
consistent agreement between planned and delivered doses, underscoring the
mechanical and dosimetric stability of the system and the effectiveness of the
image-guided setup. The advanced inverse planning algorithms tailored for
RapidArc enabled the generation of plans that met all clinical criteria,
demonstrating the technique's capacity for high-quality, conformal treatment
delivery efficiently.

354 *4.4 Comparison with Literature and Clinical Implications*

Our dosimetric outcomes align well with findings from recent SBRT studies. For
example, the PACE-B trial reported a prostate $D_{95\%}$ of approximately 34.7 Gy, similar
to our results, confirming the adequacy of target coverage [1, 3]. The slightly higher
bladder Dmax in our cohort suggests that further refinement of planning constraints
could enhance OAR sparing. The combination of rapid treatment times and intra-
fraction CBCT imaging before each arc effectively reduces setup uncertainties and
potential prostate motion during treatment. This approach allows for immediate
verification and correction, ensuring high precision in dose delivery without the
need for continuous intra-fraction tracking devices [12]. Although some plans
exhibited higher doses to the bladder, ongoing optimization of planning
constraints—such as tighter OAR limits and adaptive planning—may further
improve normal tissue sparing without compromising tumor coverage.

367 *4.5 Limitations and Future Directions*

This study's limitations include its retrospective, single-institution design and a
modest sample size (n=24). The absence of continuous intra-fraction motion
tracking means that some prostate motion during treatment was not directly
monitored, which could impact dose accuracy. Incorporating intra-fraction imaging
or adaptive techniques, such as MR-guided radiotherapy, could further enhance
treatment precision in future applications [12]. Exploring different arc
configurations, dose escalation schemes, and adaptive planning approaches can
optimize therapeutic outcomes. Larger, prospective studies are necessary to
validate these findings and compare various motion management strategies.

Leaf Speed Distribution

Figure 6: Distribution of MLC leaf speed data during treatment delivery,
demonstrating variations in leaf velocity required for dose modulation and
conformity.

As shown in Figure 6, the histogram of multileaf collimator (MLC) leaf speeds during
treatment demonstrates that the majority of leaves remained stationary or moved
very slowly, with speeds clustered near zero and a mean of 0.59 cm/s. Only a few
instances of higher leaf speeds were observed, with a maximum of approximately
2.3 cm/s—well below the mechanical limit of 2.5 cm/s defined for the Varian
Millennium 120 MLC system[21]. The narrow distribution suggests controlled and
deliberate MLC motion, with minimal rapid transitions or complex modulation. This
behavior reflects precise beam shaping and low risk of mechanical inaccuracies,
thereby contributing to accurate and safe dose delivery [5]. Overall, the observed
speed profile indicates that the plan was executed smoothly, consistent with a well-
optimized and safety-focused treatment strategy.

4.6 Comparison of MLC Leaf Motion Relative to Isocenter (Center of PTV)

In this study, we performed an in-depth analysis of MLC leaf dynamics during
radiotherapy delivery, focusing on the positional behavior of specific leaf groups
relative to the isocenter, which was positioned at the center of the PTV (Planning

Target Volume). We compared the movement patterns of the offset leaves (leaves 1
to 10) and the leaves located adjacent to the isocenter (leaves 30 to 40).

Offset Leaves (1-10)

Figure 7: MLC leaf positions (leaves 1–10) over time during treatment,
illustrating dynamic movements to shape the beam.

As illustrated in Figure 7, these leaves, positioned away from the isocenter, showed
relatively stable positions throughout the treatment duration. Leaf 8 and 9
remained nearly stationary, indicating minimal modulation, likely serving as fixed
field boundaries. In contrast, leaf 10 demonstrated significant and rapid positional
shifts after approximately 60 seconds, suggesting active modulation to
accommodate treatment requirements or compensate for patient movement.

Leaves Adjacent to Isocenter (30-40)

Figure 8 depicts the movement patterns of the leaves located near the isocenter,
which was placed at the center of the PTV. These leaves exhibited continuous
fluctuations and abrupt positional changes over the course of the treatment
session.This dynamic behavior reflects the necessity for precise modulation near the
target to achieve conformal dose delivery while sparing surrounding healthy tissue.

414
Figure 8: MLC leaf positions (leaves 30–40) over time, showing adjustments in
outer bank leaves for beam shaping and dose control.

4.7 Study Strengths and Generalisability

This study is strengthened by its detailed dosimetric evaluation incorporating not
only PTV and OAR metrics but also advanced parameters such as MLC leaf speed
and dynamic leaf positioning, providing a comprehensive insight into treatment
delivery accuracy. Additionally, the use of intra-fraction CBCT before each arc
enhanced treatment precision without requiring continuous motion tracking,
making the workflow efficient and clinically practical.

4.8 Clinical Significance

Our results support that SBRT delivered via RapidArc, with intra-fraction Cone
Beam Computed Tomography(CBCT) imaging before each arc [9], offers a practical
and effective treatment option for prostate cancer. This approach achieves high-
quality conformal dose distributions with efficient treatment times and robust
verification of prostate positioning during each arc, all without the need for real-
time motion tracking devices. This protocol minimizes treatment duration and setup
uncertainties, enhancing patient comfort and treatment accuracy. The intra-fraction
CBCT verification before each arc ensures precise targeting and dose delivery,
making this a reliable and accessible strategy in routine clinical practice. In
conclusion, SBRT using RapidArc combined with intra-fraction CBCT imaging before
each arc provides a promising approach for prostate radiotherapy, balancing
precision, efficiency, and safety. Future advancements in intra-fraction motion
management will further refine this modality and potentially improve clinical
outcomes.

5. Conclusions

This study reinforces the value of SBRT using advanced delivery techniques such as RapidArc for the precise and efficient treatment of prostate cancer. Daily intra-fraction CBCT imaging before each arc enhances localization accuracy by effectively managing organ motion, ensuring optimal target coverage while minimizing dose to surrounding normal tissues. The implementation of high-dose, hypofractionated regimens—such as 36.25 Gy in five fractions—demonstrated excellent dosimetric feasibility and safety. A key contribution of this work is the detailed multileaf collimator (MLC) motion analysis, which revealed a predominantly slow and stable leaf speed distribution. The limited occurrence of high-speed MLC movements supports the mechanical accuracy and consistency of plan delivery. This added layer of verification complements conventional dosimetric metrics, providing further assurance of treatment quality and safety. While RapidArc significantly shortens treatment time and improves conformity, careful adherence to bladder and rectum dose constraints remains critical to reduce toxicity risks. These findings support the continued advancement of personalized, high-precision radiotherapy strategies. Future studies should further refine motion management protocols and incorporate real-time mechanical metrics, such as MLC behavior, to enhance outcome predictability in prostate SBRT.

References

1.D. Dearnaley.: "Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomized, non-inferiority, phase 3 CHHiP trial," The. Lancet Oncology, vol. 17, no. 8, pp. 1047-1060, Aug. 2016, 10.1016/S1470-2045(16)30102-4

2. Freeman DE, King CR: Stereotactic body radiotherapy for low-risk prostate cancer. JAMA. 2018, 319:437 438. 10.1001/jama.2017.20275

3.E. Wieslander, V. Jóhannesson, P. Nilsson: Ultrahypofractionated Radiation Therapy for Prostate Cancer Including Seminal Vesicles in the Target Volume: A Treatment-planning Study Based on the HYPO-RT-PC Fractionation Schedule,. Advances in Radiation Oncology, vol. 9, no. 7, p. 101531, Jul. 2024, 10.1016/j.adro.2024.101531

4.K. Wang: Prostate Stereotactic Body Radiation Therapy: An Overview of Toxicity and Dose Response, . International Journal of Radiation Oncology*Biology*Physics, vol. 110, no. 1, pp. 237-248, May. 2021, 10.1016/j.ijrobp.2020.09.054

5. Chen, J., Cui, W., Fu, Q: Influence of maximum MLC leaf speed on the quality of
volumetric modulated arc therapy plans. Journal of Applied Clinical Medical Physics.
21:37-47. 10.1002/acm2.13020

6. Dasu A, Toma-Dasu I: Prostate Alpha/Beta Revisited - An Analysis of Clinical
Results from 14 168 Patients. Acta Oncol. 2012, 51:963-974.
10.3109/0284186X.2012.719635

7. Sun H, Wang N, Huang G, Liu X: Dosimetric comparison of fixed field dynamic
IMRT and VMAT techniques in simultaneous integrated boost radiotherapy of
prostate cancer. Medicine (Baltimore. 2023, 102:32063.
10.1097/MD.0000000000032063

8. Pandit-Taskar N, Iravani A, Lee D, Jacene H, Pryma D, Hope T: Dosimetry in
Clinical Radiopharmaceutical Therapy of Cancer: Practicality Versus Perfection in
Current Practice. J Nucl Med. 10.2967/jnumed.121.262977

9.K. Huang : Inter- and Intrafraction Uncertainty in Prostate Bed Image-Guided
Radiotherapy, International Journal of Radiation OncologyBiology, vol. 84, no. 2, pp.
402–407, Oct. 2012, doi: 10.1016/j.ijrobp.2011.12.035.

10. S. Rana, K. Rogers, T. Lee, D. Reed: Dosimetric impact of Acuros XB dose
calculation algorithm in prostate cancer treatment using RapidArc. J Can Res Ther,
vol. 9, no. 3, p. 430. 2013, 10.4103/0973-1482.119328

11. Tali TA, Khan MR: A Comparative Dosimetric Evaluation of Intensity-Modulated
Radiation Therapy (IMRT) and Three-Dimensional Conformal Radiotherapy
(3DCRT) for Prostate Cancer with Testicular Shielding. Asian Pac J Cancer Care.
2024, 9:295-301. 10.31557/apjcc.2024.9.2.295-301

12. Jmour, O., Benna, M., Champagnol: CBCT evaluation of inter- and intra-fraction
motions during prostate stereotactic body radiotherapy: A technical note. Radiation
Oncology. 15:84-10. 10.1186/s13014-020-015342

13. Peter Gorayski BSc (Hons): Volumetric modulated arc therapy versus step-and-
shoot intensity modulated radiation therapy in the treatment of large nerve
perineural spread to the skull base: a comparative dosimetric planning study. J Med
Radiat Sci. 2014, 61:104-11. 10.1002/jmrs.45

14. Catton CN, Lukka H, Gu C-S, et al.: Randomized Trial of a Hypofractionated
Radiation Regimen for the Treatment of Localized Prostate Cancer. J Clin Oncol.
2017, 35:1884-1890. 10.1200/JCO.2016.71.7397

15. L. N. McDermott: Clinical experience with EPID dosimetry for prostate IMRT
pre-treatment dose verification. Medical Physics, vol. 33, no. 10, pp. 3921-3930, Oct.
2006, 10.1118/1.2230810

16. Kjaer-Kristoffersen F, Ohlhues L: RapidArc volumetric modulated therapy
planning for prostate cancer patients. Acta Oncol. 2009, 48:227-232.
10.1080/02841860802266748

17. Yoo S, Wu QJ, Lee WR, Yin FF: Radiotherapy treatment plans with RapidArc for
prostate cancer involving seminal vesicles and lymph nodes. Int J Radiat Oncol Biol
Phys. 2010, 76:935-942. 10.1016/j.ijrobp.2009.07.1677

18. Jolly D, Alahakone D, Meyer J: A RapidArc planning strategy for prostate with
simultaneous integrated boost. J Appl Clin Med Phys. 2011, 12:3320.
10.1120/jacmp.v12i1.3320

19. Kinhikar RA, Pawar AB, Mahantshetty U, Dheshpande DD: RapidArc, helical
tomotherapy, sliding window IMRT and 3D conformal radiation for localized
prostate cancer: a dosimetric comparison. J Cancer Res Ther. 2014, 10:575-582.
10.4103/0973-1482.138200

20. S. Rana, K. Rogers, S. Pokharel: Evaluation of Acuros XB algorithm based on
RTOG 0813 dosimetric criteria for SBRT lung treatment with RapidArc, J Applied
Clin Med Phys, vol. 15, no. 1, pp. 118-129, Jan. 2014, 10.1120/jacmp.v15i1.4474

21. X. Lin, T. Sun: Comparison of MLC positioning deviations using log files and
establishment of specific assessment parameters for different accelerators with
IMRT and VMAT, Radiat Oncol, vol. 17, no. 1, Dec. 2022, doi: 10.1186/s13014-022-
02097-0